RCMNY
CGEM icon

Rubric Capital Management (New York)’s Cullinan Oncology CGEM Stock Holding History

Rubric Capital Management (New York)’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-626,929
Closed -$10.7M – 70
2024
Q1 		$10.7M Hold
626,929
– – 0.32% 55
2023
Q4 		$6.39M Hold
626,929
– – 0.13% 51
2023
Q3 		$5.67M Hold
626,929
– – 0.21% 55
2023
Q2 		$6.75M Hold
626,929
– – 0.29% 52
2023
Q1 		$6.41M Hold
626,929
– – 0.17% 61
2022
Q4 		$6.61M Buy
626,929
+67,192
+12% +$816K 0.29% 68
2022
Q3 		$7.18M Buy
559,737
+262,390
+88% +$3.54M 0.36% 57
2022
Q2 		$3.81M Buy
+297,347
New +$3.37M 0.2% 68

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Rubric Capital Management (New York)'s CGEM Position: Q2 2024 in Review

Rubric Capital Management (New York) sold out of Cullinan Oncology (CGEM) in Q2 2024, closing a stake of 626,929 shares — an estimated $10.7M sold.

Rubric Capital Management (New York) first reported a position in CGEM in Q2 2022 and held it in 8 quarters. The position peaked at $10.7M in Q1 2024. 135 funds tracked by Wall St. Rank hold CGEM as of Q2 2024.

  • Rubric Capital Management (New York) reported no remaining Cullinan Oncology position as of Q2 2024 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 626,929 Cullinan Oncology shares in Q2 2024, an estimated $10.7M.
  • Rubric Capital Management (New York) first reported a position in Cullinan Oncology in Q2 2022 and held it in 8 quarters.
  • Rubric Capital Management (New York)'s Cullinan Oncology position peaked at $10.7M in Q1 2024.
  • 135 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2024.

Based on Rubric Capital Management (New York)'s 13F filing for Q2 2024, filed 13 Aug 2024.